Showing 5231-5240 of 5693 results for "".
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/2479537/Allergan and Molecular Partners announced that the FDA has accepted a biologics license application (BLA) and the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for Abicipar pegol, a novel, investigational DARPin therapy in patients with wet age-related
- MST Innovations Introduces the Scleral IOL Fixation Solutions Packhttps://modernod.com/news/mst-innovations-introduces-the-scleral-iol-fixation-solutions-pack/2476857/MicroSurgical Technology has introduced the Scleral IOL Fixation Solutions Pack, which is designed to streamline the double-needle scleral IOL fixation technique with several unique new instruments that are conveniently packaged to support the procedure end-to-end. The comprehensive offeri
- iSTAR Medical Announces EUR 40 Million Series C Financinghttps://modernod.com/news/istar-medical-announces-eur-40-million-series-c-financing/2479542/iSTAR Medical announced the completion of a €40m Series C financing to support the development of iSTAR Medical’s MINIject device along the path to commercialization in Europe and the United States. MINIject, an ab-interno MIGS device, provides a powerful and reliable sol
- Kowa Submits IND Application to the FDA to Begin Phase 2 Study of Ripasudil Hydrochloride Hydratehttps://modernod.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/Kowa, which has been developing Ripasudil Hydrochloride Hydrate, a Rho kinase inhibitor, for the indication of corneal endothelial diseases, submitted an investigational new drug (IND) application to the FDA on August 30, 2019 in order to commence a phase 2 clinical
- Oculus Release Myopia Master for Myopia Managementhttps://modernod.com/news/oculus-release-myopia-master-for-myopia-management/2476839/Oculus has introduced the Myopia Master, a device designed to combine all the important measurement methods of myopia management: axial length, refraction values, and the central corneal radii. The Oculus Myopia Master creates a myopia report for each patient, giving due consideration to s
- Lenstec Completes FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-fda-trial-for-sbl-3-iol/2476837/Lenstec announced that it has completed its FDA trial for the SBL-3 IOL (Segmented Bifocal Lens), an asymmetric multifocal refractive IOL designed to provide patients with superior near, intermediate, and distance vision. It also offers improved contrast sensitivity and minimizes halos and glare
- Japan Conducts World’s First Transplant With iPS Cells for Corneal Diseasehttps://modernod.com/news/japan-conducts-worlds-1st-transplant-with-ips-cells-for-corneal-disease/2476836/A research team from Japan’s Osaka University said Thursday that it has conducted the world’s first transplant for corneal disease using induced pluripotent stem (iPS) cells. The team conducted the surgery in July, allowing iPS corneal tissues to replace the current queuing for cornea
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor